Cristers, a France-based pharmaceutical company that markets generic and OTC products, has chosen Adents Prodigi cloud serialisation solution to ensure compliance with the EU Falsified Medicines Directive and offer beyond-compliance ROI, it was reported yesterday.
Adents Prodigi is jointly developed with Microsoft and powered by Azure and is claimed to enable secure data exchange and help leverage the power of serialisation data to improve business practices. Adents serialisation solutions are designed to help companies to receive simplified speed to compliance with regulatory requirements.
The Adents Prodigi cloud-based Level 4 traceability solution met all of Cristers' requirements. The company says that the solution mainly manages regulatory requirements, offers an easy on-boarding process to connect multiple trading partners, and facilitates significant business improvements by allowing companies to use the massive amounts of data generated during the serialisation and track & trace process.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules